It took a team of researchers more than 18 months to get their paper on epigenetic variation published—likely because they are saying that epigeneticists have been fishing in the wrong pond for a decade.
Data published in The Journal for ImmunoTherapy of Cancer show ClearNote Health’s epigenomic platform may provide a novel tissue-free, liquid biopsy-based approach for prediction and monitoring of immunotherapy response for non-small cell lung cancer patients.
